Hi Timomo. That was the original number analysts estimated for Trofinetide, Neuren’s FDA approved drug. As it turns out the actual drug cost will be $375k per patient per annum. Hence the daily re-rate upwards for Neuren.
Pricing for BOT will be similar to Qbrexa or at a slight premium to it. This has been stated by Howe in the latest investor video.
Ann: Investor Presentation, page-33
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.020(5.48%) |
Mkt cap ! $543.4M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 35.5¢ | 34.0¢ | $4.566M | 13.13M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 410003 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 346713 | 8 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |